Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models
about
Bridging the gap between basic and applied biology: towards preclinical translationAlpha-synuclein Toxicity in the Early Secretory Pathway: How It Drives Neurodegeneration in Parkinsons DiseaseThe benefits of humanized yeast models to study Parkinson's diseasePhosphorylation modulates clearance of alpha-synuclein inclusions in a yeast model of Parkinson's diseaseOxidative stress in Alzheimer's and Parkinson's diseases: insights from the yeast Saccharomyces cerevisiaeC-Terminal Tyrosine Residue Modifications Modulate the Protective Phosphorylation of Serine 129 of α-Synuclein in a Yeast Model of Parkinson's Disease.Seeking a mechanism for the toxicity of oligomeric α-synucleinEngineering enhanced protein disaggregases for neurodegenerative diseaseTargeting the intrinsically disordered structural ensemble of α-synuclein by small molecules as a potential therapeutic strategy for Parkinson's diseaseGeneration of SNCA Cell Models Using Zinc Finger Nuclease (ZFN) Technology for Efficient High-Throughput Drug ScreeningCaenorhabditis elegans: a model to investigate oxidative stress and metal dyshomeostasis in Parkinson's diseaseSynphilin-1 enhances α-synuclein aggregation in yeast and contributes to cellular stress and cell death in a Sir2-dependent mannerResponseNet: revealing signaling and regulatory networks linking genetic and transcriptomic screening data.Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models.TorsinA and the torsinA-interacting protein printor have no impact on endoplasmic reticulum stress or protein trafficking in yeast.Calcineurin determines toxic versus beneficial responses to α-synuclein.Yeast reveal a "druggable" Rsp5/Nedd4 network that ameliorates α-synuclein toxicity in neurons.Cyclin-G-associated kinase modifies α-synuclein expression levels and toxicity in Parkinson's disease: results from the GenePD Study.Differences of cytotoxicity of orthodontic bands assessed by survival tests in Saccharomyces cerevisiae.Clioquinol promotes the degradation of metal-dependent amyloid-β (Aβ) oligomers to restore endocytosis and ameliorate Aβ toxicity.Isolating potentiated Hsp104 variants using yeast proteinopathy modelsα-Synuclein binds the K(ATP) channel at insulin-secretory granules and inhibits insulin secretion.Different 8-hydroxyquinolines protect models of TDP-43 protein, α-synuclein, and polyglutamine proteotoxicity through distinct mechanisms.Functional links between Aβ toxicity, endocytic trafficking, and Alzheimer's disease risk factors in yeast.Small Molecules Detected by Second-Harmonic Generation Modulate the Conformation of Monomeric α-Synuclein and Reduce Its Aggregation in Cellsα-Synuclein Shows High Affinity Interaction with Voltage-dependent Anion Channel, Suggesting Mechanisms of Mitochondrial Regulation and Toxicity in Parkinson Disease.A predictable worm: application of Caenorhabditis elegans for mechanistic investigation of movement disorders.Tunable and reversible drug control of protein production via a self-excising degron.Hsp31 Is a Stress Response Chaperone That Intervenes in the Protein Misfolding ProcessRapid profiling of disease alleles using a tunable reporter of protein misfolding.Induced pluripotent stem cell technology for disease modeling and drug screening with emphasis on lysosomal storage diseasesPhenotypic screens for compounds that target the cellular pathologies underlying Parkinson's diseaseFasudil attenuates aggregation of α-synuclein in models of Parkinson's diseaseChemical suppression of defects in mitotic spindle assembly, redox control, and sterol biosynthesis by hydroxyurea.Splice isoform and pharmacological studies reveal that sterol depletion relocalizes α-synuclein and enhances its toxicityEmergence and natural selection of drug-resistant prions.Mitochondrial involvement in cell death of non-mammalian eukaryotes.TDP-43 toxicity in yeast.Molecular chaperones and associated cellular clearance mechanisms against toxic protein conformers in Parkinson's disease.Aggresome formation and segregation of inclusions influence toxicity of α-synuclein and synphilin-1 in yeast.
P2860
Q24288827-08AE7E09-26F3-4BF8-8BBC-C82F384B8F8BQ26776209-7C405510-1567-4710-95A6-5D2409A6D969Q26853041-5F1EFBA8-82F3-4AAA-AB46-1A9CBA79C0A4Q27316174-0F07D986-8964-4763-A47C-7AE1B81DCCC8Q27692067-142E2ACB-88E3-48D8-AE09-0E16C5C2050FQ27931024-ADD98FCF-0239-4BAE-8BB3-0374F4800779Q28080551-E7D3E434-4CDA-4FF2-B68B-B3C11FB00890Q28083809-16E8C219-230D-4BB3-B117-73CFCCD2FF06Q28539839-D66656DB-3450-4BB1-A2A9-F93ABB055EE8Q28547585-A170C4BF-A9C9-4667-A26C-EC99EB66C4EAQ33658107-01D5B764-EA79-4D80-A222-6355093B1AD4Q33742140-3D702D77-A43C-411D-9812-124A8B48374BQ33901921-0B21BE4A-F001-40A2-942B-333ADC71ACB9Q33964804-75578AED-2920-4AA7-BD77-F204F41D040FQ33983398-4CAEEB31-68D7-4F55-B97B-46F69D3744DBQ34120215-3B71CBCB-F79F-47E4-B3C6-1B8D5AD642CDQ34380191-67141DCF-E505-49EB-8AB2-5A100D34F6E9Q34718087-6CFA4819-58A2-4539-9C9F-6D05CFFCD0DFQ35089767-3D78D0CF-3F8D-4F86-B79D-E242017BCF5AQ35109915-DBDC305A-DB95-433A-9F83-E56A021D166EQ35434297-3C36B470-0DBA-4BDB-A4FC-B93DE660B3BDQ35696031-2223C7DA-7BDC-40CF-B3E7-215246909D36Q35763165-C4A76E26-3BC1-4E4C-A733-795D67A7B435Q35763361-0ECF5F75-848B-40D3-BB45-2EB40A1AB7E9Q35784396-17605A39-0F88-4DF7-9BBF-774533DB3E59Q35883815-1A136838-C089-4AF7-A90F-EF6E63C3FDC5Q35913800-2ECF35BB-4B87-4D1B-B738-BB2B8815554DQ35977821-6749016F-5D86-47ED-BC5C-D769539FE71CQ36139835-28B1DA88-2440-4A8C-A8FA-571803D55230Q36466309-92B4F861-7D2E-4855-AEBF-4BAB88E7B18AQ36633022-79FE8EED-5398-49F5-889E-AF6A27A12C30Q36810598-B2353FC8-A609-464E-B92E-36D0E86C8911Q36825541-319796CC-BE47-4D0C-A1B2-B152F2D137DBQ37460720-B471B46E-D888-49E7-9094-2A55D6A67B32Q37612718-E3A3B55F-A992-4455-A5FD-5C6B72A6E5E4Q37737577-96C29C03-A0FC-4126-9A46-3D634799014FQ37800527-0B94404A-BA05-4734-8839-BB971BD07E78Q37813221-297235E1-37CD-4304-8A03-AC536B551E5FQ37853789-41508A52-0CE0-4ECC-89FD-EB2C7967DF30Q37936556-AB5F7F3F-3261-45F6-8532-9583D064DA83
P2860
Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Compounds from an unbiased che ...... in Parkinson's disease models
@ast
Compounds from an unbiased che ...... in Parkinson's disease models
@en
Compounds from an unbiased che ...... in Parkinson's disease models.
@nl
type
label
Compounds from an unbiased che ...... in Parkinson's disease models
@ast
Compounds from an unbiased che ...... in Parkinson's disease models
@en
Compounds from an unbiased che ...... in Parkinson's disease models.
@nl
prefLabel
Compounds from an unbiased che ...... in Parkinson's disease models
@ast
Compounds from an unbiased che ...... in Parkinson's disease models
@en
Compounds from an unbiased che ...... in Parkinson's disease models.
@nl
P2093
P2860
P50
P921
P356
P1476
Compounds from an unbiased che ...... in Parkinson's disease models
@en
P2093
Antony A Cooper
Daniel F Tardiff
Guy A Caldwell
J Michael McCaffery
Jean-Christophe Rochet
Joshua A Kritzer
Katherine E Strathearn
Kathryn J Hill
Kim A Caldwell
P2860
P304
P356
10.1242/DMM.004267
P577
2009-12-28T00:00:00Z